Compare GWAV & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GWAV | CNSP |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 3.8M |
| IPO Year | 2014 | 2019 |
| Metric | GWAV | CNSP |
|---|---|---|
| Price | $3.80 | $3.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 23.4K | 17.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,098,036.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 116184.26 | N/A |
| 52 Week Low | $0.07 | $0.73 |
| 52 Week High | $24.00 | $10.59 |
| Indicator | GWAV | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 38.83 | 23.35 |
| Support Level | $3.29 | $0.77 |
| Resistance Level | $7.22 | $8.89 |
| Average True Range (ATR) | 0.31 | 0.29 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 34.51 | 7.75 |
Greenwave Technology Solutions Inc through its subsidiary, is an operator of several metal recycling facilities in Virginia, Ohio and North Carolina. At these facilities, the company is involved in collecting, classifying, and processing raw scrap metal (ferrous and nonferrous) for recycling. The company involves collecting, classifying and processing appliances, construction material, end-of-life vehicles, boats, and industrial machinery and processing those items by crushing, shearing, shredding, separating, and sorting, into smaller pieces and categorize these recycled ferrous, nonferrous, and mixed metal pieces based on density and metal prior to sale.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.